Fidelity Disruptive Technology ETF (FDTX)

The Fidelity Disruptive Technology ETF (ticker FDTX) is an actively managed exchange-traded fund that invests in companies whose products, services, or business models are expected to disrupt traditional industries or create new markets. Rather than tracking an index, the fund’s managers select holdings based on their conviction that certain technological trends — including artificial intelligence, genomics, cloud computing, fintech, and advanced manufacturing — will reshape how society and commerce function.

Financial Technology and Payments

One segment of FDTX’s portfolio focuses on companies reshaping how financial transactions, lending, and investment management work. This includes blockchain and cryptocurrency infrastructure, digital payment rails, alternative lending platforms, and wealth-management software. These companies exist both as public firms offering fintech services directly and as technology providers selling to traditional financial institutions seeking to modernize their systems. Fintech disruption has created winners in transaction processing, identity verification, and risk management, though the segment also carries the volatility of companies with young business models and uncertain regulatory futures.

Artificial Intelligence and Computational Capability

A second major theme in FDTX is artificial intelligence — both companies building large language models and training infrastructure, and firms deploying AI to solve domain-specific problems. This includes chip designers (especially those focused on AI acceleration), cloud-computing providers offering AI tools, and software companies embedding machine learning into their products. The appeal of AI-focused holdings lies in the expectation that large-scale computational inference will become a fundamental input to many industries, but the exact pace of adoption and the durability of competitive advantages remain contested.

Life Sciences and Genomics

FDTX also allocates meaningfully to life sciences, including gene-editing technologies, precision medicine platforms, and computational biology. These companies range from biotechnology firms developing therapies based on genetic sequencing, to diagnostics companies using genomic data to personalise treatment, to research-tool makers enabling genomic science. This segment reflects the thesis that our ability to read, edit, and act on genetic information will drive a wave of new medicines and preventive health approaches, though it is also one of the slowest to deliver returns because drug development and regulatory approval are lengthy processes.

Advanced Manufacturing and Materials

A third focus includes companies enabling new manufacturing paradigms — additive manufacturing (3D printing), advanced robotics for production, and new materials with novel properties (polymers, composites, semiconductors from alternative processes). These companies tend to be business-to-business, selling equipment and services to factories, electronics makers, and industrial operators seeking to boost efficiency, reduce waste, or create products previously impossible to manufacture. The disruption theme here is about how manufacturing itself is being digitised and automated.

Cloud Infrastructure and Data Systems

FDTX maintains exposure to cloud computing, data analytics, and cybersecurity infrastructure. These underpin the computational backbone on which other disruptive technologies rest — cloud platforms making it cheap to run distributed computing, databases optimised for AI workloads, and security tools protecting against evolving threats. Because many fintech, AI, and genomics companies run on cloud infrastructure, there is some overlap, but this segment also includes pure-infrastructure plays that are essential enabling layers for broader digital transformation.

Active management and the cost question

Unlike passive index-tracking ETFs, FDTX charges an active management fee. Fidelity’s managers are tasked with identifying which disruptive technologies are most likely to succeed and which companies are best positioned to benefit. This introduces both opportunity and risk: the fund could outperform if its bets on specific technologies and specific company winners prove correct, but it could also underperform if the managers’ selections do not work out or if the market reprices the value of the bets they have made.

The fund holds roughly 40 to 60 stocks, giving it a concentrated portfolio. This concentration amplifies both gains and losses, and means the fund can deviate significantly from broad market indices. Investors in FDTX are implicitly betting that Fidelity’s active selection adds value above the expense ratio, which is higher than a passive alternative.

Who FDTX serves and research approach

FDTX is most suited to investors with above-average risk tolerance who believe disruptive technologies will outperform traditional sectors over a multi-year period, and who are comfortable with the volatility, concentration, and active-fee structure that come with that thesis. The fund appeals to growth-oriented investors who want technology exposure but prefer Fidelity’s discretion over a strict index formula.

Investors evaluating FDTX should read the fund’s fact sheet to see the current top holdings and their sector breakdown. Because the portfolio is actively managed, the holdings change regularly as managers reassess their convictions. Prospective investors should consider whether the themes FDTX emphasizes (AI, fintech, genomics, etc.) align with their own view of which technologies will deliver returns. The fund’s volatility, particularly during market downturns in growth stocks, is a key characteristic to understand before investing.